clinical trial · NCT04539236
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Mikkael Sekeres, MD·phase2·suspended·n = 50
Myelodysplastic SyndromesLenalidomideLuspatercept
brief summary
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
started
Nov 9, 2021
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Aug 5, 2025
official title
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol